FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program Read more
IOM: Report on Conflict of Interest: Maybe Best of Intentions but Overreliance on Distant Past Read more